Tumor markers play a pivotal role in precision oncology by linking molecular characteristics of cancer to targeted therapeutic strategies. Advances in biomarker discovery, including genomic, proteomic, and circulating tumor markers, have greatly improved patient stratification, treatment selection, and disease monitoring.

This column, Tumor Markers and Targeted Therapy, focuses on recent developments in biomarker-driven targeted treatments across solid and hematological malignancies. By highlighting emerging markers, mechanisms of therapeutic resistance, and clinical translation, this collection aims to advance the understanding and application of tumor markers in personalized cancer therapy.